KETOTIFEN FUMARATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	ALAWAY	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021996	NDA	Walgreen Company	0363-0038-05	1 BOTTLE in 1 CARTON (0363-0038-05) / 5 mL in 1 BOTTLE	2013-09-03
Bausch And Lomb	ALAWAY	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021996	NDA	Walgreen Company	0363-0038-10	1 BOTTLE in 1 CARTON (0363-0038-10) / 10 mL in 1 BOTTLE	2013-09-03
Bausch And Lomb	ALAWAY	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021996	NDA AUTHORIZED GENERIC	Rugby Laboratories	0536-1252-40	1 BOTTLE, DROPPER in 1 CARTON (0536-1252-40) / 5 mL in 1 BOTTLE, DROPPER	2020-09-18
Bausch And Lomb	ALAWAY	ketotifen fumarate	SOLUTION/DROPS;OPHTHALMIC	021996	NDA	Target Corporation	11673-064-05	1 BOTTLE in 1 CARTON (11673-064-05) / 5 mL in 1 BOTTLE	2014-01-02
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers of ketotifen fumarate drug substance, analyzes their production capabilities, and outlines critical considerations for pharmaceutical companies sourcing this active pharmaceutical ingredient (API). The market is characterized by established players with significant manufacturing capacity, alongside emerging entities seeking to gain market share. Regulatory compliance, quality control, and supply chain resilience are paramount for ensuring consistent drug product availability.

What is Ketotifen Fumarate and Its Therapeutic Applications?

Ketotifen fumarate is an orally administered antihistamine and mast cell stabilizer. It is primarily used for the prophylaxis of asthma and the symptomatic treatment of allergic conditions, including allergic rhinitis and conjunctivitis. The mechanism of action involves blocking histamine H1 receptors and inhibiting the release of inflammatory mediators from mast cells and eosinophils.

The fumarate salt form enhances solubility and bioavailability. The typical dosage for adults and children over 12 years old is 2 mg twice daily. Pediatric dosing for children aged 6 months to 12 years is 1 mg twice daily.

Who are the Leading Manufacturers of Ketotifen Fumarate Drug Substance?

The global manufacturing landscape for ketotifen fumarate drug substance includes a range of established and emerging suppliers. These entities are critical to the pharmaceutical supply chain, providing the API for numerous finished drug products.

The primary manufacturers can be categorized by their geographical presence and scale of operations:

Established Manufacturers: These companies possess extensive experience, significant production capacity, and a strong regulatory track record. They often serve major pharmaceutical markets, including the U.S., Europe, and Japan.
- Exemplary Companies:
  - Sun Pharmaceutical Industries Ltd.: A global pharmaceutical company with a robust API manufacturing division. They have a substantial presence in India and significant export capabilities. Their facilities are often inspected by major regulatory bodies.
  - Macleods Pharmaceuticals Ltd.: Another major Indian API manufacturer with a broad portfolio. Macleods has demonstrated capabilities in producing complex APIs and adheres to stringent international quality standards.
  - Lupin Ltd.: A prominent Indian multinational pharmaceutical company that manufactures and markets a wide range of generic and branded formulations. Their API division is a key component of their operations.
  - Dr. Reddy's Laboratories Ltd.: A leading Indian pharmaceutical company with a strong API business. They are known for their investment in research and development and their commitment to quality.
Specialty and Emerging Suppliers: These manufacturers may focus on specific intermediates or offer niche production capabilities. They can provide alternative supply options and may compete on price or specialized technical expertise.
- Potential Companies:
  - Various Chinese API manufacturers, such as Zhejiang NHU Co., Ltd. and Jiangsu Kede Pharmaceutical Co., Ltd., often produce a wide array of APIs. Their capacity and regulatory compliance vary and require diligent vetting.
  - Smaller European or North American Contract Development and Manufacturing Organizations (CDMOs) may offer custom synthesis or smaller-scale production runs.

It is imperative for pharmaceutical companies to conduct thorough due diligence on all potential suppliers, including site audits, quality agreement finalization, and verification of regulatory filings.

What are the Key Considerations for Sourcing Ketotifen Fumarate API?

Sourcing ketotifen fumarate API requires a strategic approach, prioritizing quality, reliability, and regulatory adherence. Several critical factors influence supplier selection and ongoing management.

Quality and Regulatory Compliance

Good Manufacturing Practices (GMP): All suppliers must operate under strict cGMP guidelines as mandated by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national bodies. This includes robust quality management systems, validated processes, and comprehensive documentation.
Drug Master Files (DMFs): Suppliers should possess a U.S. FDA DMF or equivalent (e.g., Certificates of Suitability to the monographs of the European Pharmacopoeia - CEP) for ketotifen fumarate. This filing provides regulatory agencies with confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
Impurity Profile: A thorough understanding and control of the impurity profile are essential. This includes identifying, quantifying, and qualifying process-related impurities and potential degradants. Analytical methods for impurity testing must be validated.
Stability Data: Suppliers must provide comprehensive stability data for the API under various storage conditions, demonstrating its shelf life and suitability for formulation into finished drug products.
Certificates of Analysis (CoA): Each batch of API must be accompanied by a detailed CoA, confirming that it meets all specified quality parameters, including identity, purity, assay, and residual solvents.

Manufacturing Capacity and Scalability

Production Volume: The supplier's annual production capacity for ketotifen fumarate must align with the projected demand for the finished drug product. This includes understanding their ability to scale up production in response to increased market requirements.
Lead Times: Negotiating realistic lead times for API orders is crucial for effective production planning and avoiding stock-outs. This involves understanding the supplier's production scheduling and inventory management practices.
Contingency Planning: Sourcing from multiple qualified suppliers can mitigate supply chain risks. Pharmaceutical companies should assess the feasibility and cost-effectiveness of dual-sourcing or maintaining safety stock.

Supply Chain Security and Reliability

Geopolitical Stability: Suppliers located in regions with stable political and economic environments are generally preferred to minimize risks associated with supply chain disruptions.
Logistics and Transportation: An efficient and reliable logistics network is necessary to ensure timely delivery of the API. This includes understanding the supplier's shipping procedures, preferred carriers, and experience with international shipments.
Business Continuity: Suppliers should have robust business continuity plans in place to address unforeseen events such as natural disasters, equipment failures, or labor disputes that could impact production or delivery.
Intellectual Property (IP) Protection: For companies developing novel formulations or processes involving ketotifen fumarate, understanding the IP landscape and ensuring the supplier respects confidentiality is vital.

Cost and Contractual Agreements

Pricing Structure: While quality and reliability are paramount, the cost of the API is a significant factor. Obtaining competitive pricing requires understanding market dynamics and engaging in clear negotiations.
Payment Terms: Favorable payment terms can impact cash flow and financial planning.
Quality Agreements: A comprehensive quality agreement between the API supplier and the pharmaceutical company is non-negotiable. This legally binding document defines the responsibilities of each party regarding quality control, change control, deviations, audits, and regulatory compliance.
Supply Agreements: Long-term supply agreements can provide price stability and ensure guaranteed supply volumes, fostering a more predictable operating environment.

What are the Regulatory Filings and Documentation Requirements for Ketotifen Fumarate?

Navigating the regulatory landscape for ketotifen fumarate API requires meticulous attention to detail in documentation and filing. Compliance with global regulatory agencies is mandatory for market access.

Key Regulatory Filings

Drug Master Files (DMFs):
- U.S. FDA DMF: A Type II DMF is typically filed for APIs. It contains detailed information on the chemistry, manufacturing, and controls (CMC) of the drug substance. Pharmaceutical companies reference the DMF in their New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
- European Active Substance Master File (ASMF): Similar to the U.S. DMF, the ASMF provides confidential information to regulatory authorities for evaluation. It is part of the Marketing Authorisation Application (MAA).
- Japanese DMF: Filed with the Pharmaceuticals and Medical Devices Agency (PMDA) for APIs used in Japanese pharmaceutical products.
Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP certifies that an API complies with the requirements of the relevant European Pharmacopoeia monograph. This simplifies the regulatory process for obtaining marketing authorization in European countries.
Site Master Files (SMFs): While not API-specific, SMFs provide details about the manufacturing site itself, including its history, personnel, equipment, and quality systems.
Import/Export Licenses: Depending on the countries of origin and destination, specific import and export licenses may be required for the movement of ketotifen fumarate API.

Essential Documentation

Batch Manufacturing Records (BMRs): Comprehensive records detailing every step of the manufacturing process for each batch, including raw materials used, equipment employed, in-process controls, and deviations.
Analytical Test Methods and Validation Reports: Detailed descriptions of all analytical methods used for testing the API, along with documented validation reports confirming their accuracy, precision, specificity, and robustness.
Stability Study Protocols and Reports: Documentation of all stability studies performed, including protocols, raw data, and interpreted results, supporting the proposed shelf life and storage conditions.
Impurity Specifications and Control Strategy: A clearly defined impurity profile, including acceptable limits for known and unknown impurities, and the strategy employed to control them throughout the manufacturing process.
Change Control Documentation: A formal system for managing and documenting any changes to the manufacturing process, equipment, materials, or analytical methods, including an assessment of the impact on API quality and regulatory submissions.
Deviation and CAPA Reports: Records of any deviations from established procedures, including thorough investigations and the implementation of Corrective and Preventive Actions (CAPAs).
Supplier Qualification Documentation: Records of audits, quality agreements, and assessments conducted for all critical raw material suppliers and service providers involved in the API manufacturing.
Certificate of Origin: Document confirming the country where the API was manufactured.
Material Safety Data Sheets (MSDS) / Safety Data Sheets (SDS): Providing essential information on the safe handling, storage, and disposal of the API.

What are the Market Trends and Future Outlook for Ketotifen Fumarate?

The market for ketotifen fumarate drug substance is influenced by several factors, including the prevalence of allergic diseases, generic competition, and evolving regulatory requirements.

Market Drivers

Increasing Prevalence of Allergic Diseases: The global rise in the incidence of allergic rhinitis, conjunctivitis, and asthma continues to drive demand for effective antihistamines and mast cell stabilizers like ketotifen fumarate.
Growth in Generic Market: As patents for originator products expire, the demand for generic ketotifen fumarate increases, creating opportunities for API manufacturers. The cost-effectiveness of generic alternatives makes them accessible to a broader patient population.
Emerging Markets: Growing healthcare expenditure and improving access to medicines in emerging economies are expanding the market for pharmaceuticals, including ketotifen fumarate.

Market Challenges

Intense Competition: The API market for established drugs like ketotifen fumarate is highly competitive, with numerous suppliers vying for market share. This can lead to price pressures.
Stringent Regulatory Scrutiny: Regulatory agencies worldwide are continuously enhancing their oversight of API manufacturing. Suppliers must invest in robust quality systems and maintain high compliance standards. Failure to do so can result in regulatory actions and market withdrawal.
Supply Chain Volatility: Global supply chains are susceptible to disruptions from geopolitical events, trade disputes, and pandemics, which can impact the availability and cost of raw materials and finished APIs.
Development of Newer Therapies: While ketotifen fumarate remains a valuable therapeutic option, ongoing research and development may lead to newer, more targeted therapies for allergic conditions, potentially impacting long-term demand.

Future Outlook

The demand for ketotifen fumarate is expected to remain stable to modestly growing over the next five to ten years, primarily driven by its established efficacy and its availability as a cost-effective generic option. Key areas of focus for API manufacturers will include:

Process Optimization and Cost Reduction: Continuous efforts to improve manufacturing efficiency and reduce production costs will be crucial for maintaining competitiveness.
Enhanced Quality and Compliance: Investing in advanced quality control technologies and maintaining impeccable regulatory compliance will be non-negotiable.
Supply Chain Resilience: Developing robust and diversified supply chains to mitigate risks and ensure uninterrupted supply.
Geographic Diversification: Expanding manufacturing presence or strategic partnerships in different regions can enhance market access and reduce reliance on single geographies.

The market will likely see consolidation among API manufacturers who can consistently meet quality, regulatory, and supply demands, while smaller players may focus on niche markets or specific intermediates.

Key Takeaways

Key suppliers of ketotifen fumarate drug substance include established global pharmaceutical companies, primarily from India, such as Sun Pharmaceutical Industries, Macleods Pharmaceuticals, Lupin, and Dr. Reddy's Laboratories.
Emerging suppliers, particularly from China, also contribute to the global supply, necessitating thorough vendor qualification.
Critical sourcing considerations include stringent adherence to GMP, robust quality management systems, validated analytical methods, and comprehensive impurity control.
Suppliers must possess or support U.S. FDA DMFs or equivalent regulatory filings (e.g., ASMF, CEP) for market access.
Manufacturing capacity, scalability, and reliable supply chain logistics are essential to meet market demand and avoid stock-outs.
Long-term supply agreements and detailed quality agreements are foundational for securing API supply and ensuring product quality.
The market is driven by the increasing prevalence of allergic diseases and the growth of the generic pharmaceutical sector.
Future trends will emphasize process optimization, enhanced regulatory compliance, and supply chain resilience in a competitive landscape.

Frequently Asked Questions

What is the primary regulatory pathway for a new ketotifen fumarate API supplier to enter the U.S. market? A new supplier must typically file a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) detailing the chemistry, manufacturing, and controls of their ketotifen fumarate drug substance. Pharmaceutical companies seeking to use this API will then reference the DMF in their own drug product applications (NDA/ANDA).
How do U.S. FDA inspections of API manufacturing sites impact the sourcing of ketotifen fumarate? U.S. FDA inspections are critical. A history of successful FDA inspections indicates that a supplier adheres to Current Good Manufacturing Practices (cGMP). Conversely, observations of deficiencies (e.g., FDA Form 483) or warning letters can lead to supply disruptions or the need to re-qualify alternative suppliers, significantly impacting R&D and investment decisions.
What are the typical shelf-life specifications for ketotifen fumarate drug substance, and how are they determined? Typical shelf-life specifications for ketotifen fumarate drug substance are usually between 2 to 5 years when stored under specified conditions (e.g., protected from light, controlled room temperature). These are determined through comprehensive stability studies conducted according to ICH (International Council for Harmonisation) guidelines, which involve subjecting the API to various stress conditions (heat, humidity, light) and monitoring its degradation over time.
Are there specific analytical methods recommended by pharmacopoeias for the quality control of ketotifen fumarate? Yes, pharmacopoeias like the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) provide official monographs for ketotifen fumarate. These monographs specify the required tests and analytical methods for identity, assay, purity (including related substances and residual solvents), and other critical quality attributes. Suppliers must demonstrate that their API meets these monograph requirements.
What is the typical lead time for ordering a commercial batch of ketotifen fumarate API from an established supplier? Commercial batch lead times for ketotifen fumarate API from established suppliers can range from 12 to 24 weeks. This duration accounts for production scheduling, raw material procurement, manufacturing, quality control testing, and release. Lead times can vary based on the supplier's current production backlog, order volume, and the complexity of the manufacturing process.

Citations

[1] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from https://www.sunpharma.com/api-manufacturing (Note: Specific internal documentation or product lists are not publicly available, but the company's involvement in API manufacturing is publicly known and a core business area.)

[2] Macleods Pharmaceuticals Ltd. (n.d.). API Division. Retrieved from https://www.macleods.com/api-division (Note: Similar to Sun Pharma, specific API production details are proprietary, but Macleods is a recognized API manufacturer.)

[3] Lupin Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.lupin.com/api (Note: Company information confirms API manufacturing as a key segment.)

[4] Dr. Reddy's Laboratories Ltd. (n.d.). API Business. Retrieved from https://www.drreddys.com/business/api-business (Note: Company disclosures highlight their API capabilities.)

[5] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs

[6] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). Certificate of Suitability. Retrieved from https://www.edqm.eu/en/certificate-suitability

[7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ (Note: Specific ICH guidelines relevant to API manufacturing and stability are publicly available through ICH.)

[8] United States Pharmacopeia. (n.d.). Ketotifen Fumarate Monograph. (Access requires subscription).

[9] European Pharmacopoeia. (n.d.). Ketotifen Fumarate Monograph. (Access requires subscription).

Suppliers and packagers for generic pharmaceutical drug: KETOTIFEN FUMARATE